Tibulizumab (LY 3090106) 是一种四价双特异性单克隆抗体，靶向 B 细胞激活因子 (BAFF) 和 IL-17A，Kd 值分别为 60 pM 和 14 pM。 Tibulizumab 可用于自身免疫性疾病研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 201.34 kDa.

Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 92.06%, determined by SEC-HPLC.

Tibulizumab bound to BAFF protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Tibulizumab bound hu-BAFF-Fc, and the EC50 was 0.081 nM.

Tibulizumab bound to IL-17a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Tibulizumab bound to in hu-IL-17a-His, and the EC50 was 0.128 nM.

Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Tibulizumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Tibulizumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 3.81 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.